NCT05790447 - Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

December 31, 2025

Conditions

Advanced Solid TumorRefractory Tumor

Interventions

DRUG

Thymalfasin

loading dose with thymalfasin based on the amounts of T lymphocyte

RADIATION

Radiotherapy

hypofractionated radiotherapy/SBRT

DRUG

PD-1/PD-L1 inhibitor

The PD-1/PD-L1 inhibitors are used within one week after radiotherapy

DRUG

GM-CSF

subcutaneous injection daily for 7 consecutive days

Trial Locations (1)

RECRUITING

The Second Affiliated Hospital of SchoowUniversity, Suzhou